Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate

Cancer Biology and Therapy

Volumn 13, Issue 14, 2012, Pages 1454-1462

  Wintzell, My ^a   Löfstedt, Lina ^a   Johansson, Joel ^a   Pedersen, Anne B ^a   Fuxe, Jonas ^a   Shoshan, Maria ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

3 Bromopyruvate; Chemoresistance; Cisplatin; Epithelial mesenchymal transition; Hexokinase; Tumor initiating cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; BETA ACTIN; BREAST CANCER RESISTANCE PROTEIN; BROMOPYRUVIC ACID; CARBOPLATIN; CISPLATIN; CYTOCHROME C; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; HERMES ANTIGEN; HEXOKINASE; IMATINIB; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; QUERCETIN; RESVERATROL; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; VOLTAGE DEPENDENT ANION CHANNEL;

ARTICLE; CANCER STEM CELL; CELL MOTILITY; CELL POPULATION; CELL RENEWAL; CHEMOSENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; OVARY CARCINOMA; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; ASCITES; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; ISOENZYMES; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT; PYRUVATES; RETINAL DEHYDROGENASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84870667447     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22007     Document Type: Article

References (49)

1. Tinelli A, Vergara D, Martignago R, Leo G, Pisanò M, Malvasi A. An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics 2009; 10:240-9; PMID:19949545; http://dx.doi.org/10.2174/138920209788488553.
2. Landen CN Jr., Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26:995-1005; PMID:18195328; http://dx.doi.org/10.1200/JCO.2006.07.9970.
3. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65:3025-9; PMID:15833827.
4. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311-20; PMID:18519691; http://dx.doi.org/10.1158/0008-5472.CAN-08-0364.
5. Landen CN Jr., Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010; 9:3186-99; PMID:20889728; http://dx.doi.org/10.1158/1535-7163.MCT- 10-0563.
6. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012; 18:869-81; PMID:22142828; http://dx.doi.org/10.1158/1078- 0432.CCR-11-2188.
7. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treat Rev 2012; 38:589-98; PMID:22469558; http://dx.doi.org/10. 1016/j.ctrv.2012.03.003.
8. Luo L, Zeng J, Liang B, Zhao Z, Sun L, Cao D, et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol 2011; 91:596-602; PMID:21787767; http://dx.doi.org/10. 1016/j.yexmp.2011.06.005.
9. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009; 27:2059-68; PMID:19544473; http://dx.doi.org/10.1002/stem.154.
10. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008; 14:79- 89; PMID:18598946; http://dx.doi.org/10.1016/j.ccr.2008.06.005.
11. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278:9100-6; PMID:12509415; http://dx.doi.org/10.1074/jbc.M210284200.
12. Kruidering M, Van de Water B, de Heer E, Mulder GJ, Nagelkerke JF. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 1997; 280:638-49; PMID:9023274.
13. Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007; 120:175-80; PMID:17044026; http://dx.doi.org/10.1002/ijc.22132.
14. Dehne N, Lautermann J, Petrat F, Rauen U, de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 2001; 174:27-34; PMID:11437646; http://dx.doi.org/10.1006/taap.2001.9171.
15. Olivero OA, Semino C, Kassim A, Lopez-Larraza DM, Poirier MC. Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. Mutat Res 1995; 346:221-30; PMID:7753115; http://dx.doi.org/10.1016/0165- 7992(95)90039-X.
16. Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 2011; 41:661-8; PMID:21145397; http://dx.doi.org/10.1016/j.nbd. 2010.11.017.
17. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008; 320:661-4; PMID:18388260; http://dx.doi.org/10.1126/ science.1156906.
18. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006; 25:4647-62; PMID:16892079; http://dx.doi.org/10.1038/sj.onc. 1209607.
19. Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res 2009; 19:802-15; PMID:19532122; http://dx.doi.org/10.1038/cr.2009.69.
20. Varum S, Momcilović O, Castro C, Ben-Yehudah A, Ramalho-Santos J, Navara CS. Enhancement of human embryonic stem cell pluripotency through inhibition of the mitochondrial respiratory chain. Stem Cell Res 2009; 3:142-56; PMID:19716358; http://dx.doi.org/10.1016/j.scr.2009.07.002.
21. Amuthan G, Biswas G, Ananadatheerthavarada HK, Vijayasarathy C, Shephard HM, Avadhani NG. Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells. Oncogene 2002; 21:7839-49; PMID:12420221; http://dx.doi.org/10.1038/sj.onc.1205983.
22. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M. Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2. Cell Death Differ 2009; 16:571-83; PMID:19079138; http://dx.doi.org/10.1038/cdd.2008.178.
23. Naito A, Cook CC, Mizumachi T, Wang M, Xie CH, Evans TT, et al. Progressive tumor features accompany epithelial-mesenchymal transition induced in mitochondrial DNA-depleted cells. Cancer Sci 2008; 99:1584-8; PMID:18754870; http://dx.doi.org/10.1111/j.1349-7006.2008.00879.x.
24. Scatena R. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation. Adv Exp Med Biol 2012; 942:287-308; PMID:22399428; http://dx.doi.org/10.1007/978-94-007-2869-1-13.
25. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03. 027.
26. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008; 3:e2888; PMID:18682804; http://dx.doi.org/10.1371/ journal.pone.0002888.
27. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment. Mol Cancer Ther 2009; 8:1916-23; PMID:19567816; http://dx.doi.org/10.1158/1535-7163.MCT-09-0179.
28. Björklund M, Roos J, Gogvadze V, Shoshan M. Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother Pharmacol 2011; 68:1459-67; PMID:21479886; http://dx.doi.org/10.1007/s00280-011-1640-x.
29. Shoshan-Barmatz V, Israelson A, Brdiczka D, Sheu SS. The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death. Curr Pharm Des 2006; 12:2249-70; PMID:16787253; http://dx.doi.org/10.2174/138161206777585111.
30. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002; 277:7610-8; PMID:11751859; http://dx.doi.org/10.1074/jbc.M109950200.
31. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25:4777-86; PMID:16892090; http://dx.doi.org/10. 1038/sj.onc.1209603.
32. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7; PMID:11287972; http://dx.doi.org/10.1056/NEJM200104053441401.
33. Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer 2011; 131:30-40; PMID:21796625.
34. Björklund M, Roos J, Gogvadze V, Shoshan M. Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother Pharmacol 2011; 68:1459-67; PMID:21479886; http://dx.doi.org/10.1007/s00280-011-1640-x.
35. Chen Z, Zhang H, Lu W, Huang P. Role of mitochondria- associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 2009; 1787:553-60; PMID:19285479; http://dx.doi.org/10.1016/j.bbabio.2009. 03.003.
36. Shoshan MC. 3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr 2012; 44:7-15; PMID:22298255; http://dx.doi.org/10.1007/s10863-012-9419-2.
37. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 2011; 112:2850-64; PMID:21618587; http://dx.doi.org/10.1002/jcb.23199.
38. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer 2012; 130:29-39; PMID:21480217; http://dx.doi.org/10.1002/ijc.25967.
39. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, et al. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 2012; 180:1159-69; PMID:22222226; http://dx.doi.org/10.1016/j.ajpath.2011.11.015.
40. Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer 2011; 129:820-31; PMID:21520032; http://dx.doi.org/10.1002/ ijc.25944.
41. Rehman J. Empowering self-renewal and differentiation: the role of mitochondria in stem cells. J Mol Med (Berl) 2010; 88:981-6; PMID:20809088; http://dx.doi.org/10.1007/s00109-010-0678-2.
42. Gao XN, Lin J, Gao L, Li YH, Wang LL, Yu L. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia. Leuk Res 2011; 35:1226-32; PMID:21724256; http://dx.doi.org/10.1016/j.leukres.2011. 06.010.
43. Smiraglia DJ, Kulawiec M, Bistulfi GL, Gupta SG, Singh KK. A novel role for mitochondria in regulating epigenetic modification in the nucleus. Cancer Biol Ther 2008; 7:1182-90; PMID:18458531; http://dx.doi.org/10.4161/cbt.7.8. 6215.
44. Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251:1-16; PMID:17125914; http://dx.doi.org/10.1016/j.canlet.2006.10.007.
45. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19:17-24; PMID:19101634; http://dx.doi.org/10.1016/j.semcancer.2008.11.006.
46. Ihrlund LS, Hernlund E, Khan O, Shoshan MC. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008; 2:94-101; PMID:19383331; http://dx.doi.org/10.1016/j.molonc.2008.01. 003.
47. Shulga N, Wilson-Smith R, Pastorino JG. Sirtuin-3 deacetylation of cyclophilin D induces dissociation of hexokinase II from the mitochondria. J Cell Sci 2010; 123:894-902; PMID:20159966; http://dx.doi.org/10.1242/jcs.061846.
48. Varum S, Rodrigues AS, Moura MB, Momcilovic O, Easley CA 4th, Ramalho-Santos J, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS One 2011; 6:e20914; PMID:21698063; http://dx.doi.org/10.1371/journal.pone.0020914.
49. Gong L, Cui Z, Yu X, Wei Y, Peng J, Leng X. Hexokinase II in CD133+ and CD133- hepatoma BEL-7402 Cells. Pathol Oncol Res 2012; 18:377-81; PMID:21909686; http://dx.doi.org/10.1007/s12253-011-9455-y.